Systemic toxicity with topical ophthalmic medications in children

Paediatric and Perinatal Drug Therapy

Volumn 7, Issue 1, 2006, Pages 23-29

  Gray, Claudia ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Brimonidine; Chloramphenicol; Corticosteroids; Cyclopentolate; Ophthalmic; Phenylephrine; Timolol; Toxicity

Indexed keywords

AGENTS ACTING ON THE EYE; BETAMETHASONE; BRIMONIDINE; CHLORAMPHENICOL; CORTICOSTEROID; CYCLOPENTOLATE; DEXAMETHASONE; HYDROXYAMPHETAMINE; METHYLPREDNISOLONE; PHENYLEPHRINE; PREDNISOLONE; PREDNISOLONE ACETATE; STEROID; TIMOLOL; TROPICAMIDE;

ABDOMINAL PAIN; ADRENAL SUPPRESSION; AMBLYOPIA; APLASTIC ANEMIA; APNEA; ATRIOVENTRICULAR BLOCK; BLOOD DYSCRASIA; BONE DENSITY; BRADYCARDIA; BRONCHOSPASM; CHILD; COMBINATION CHEMOTHERAPY; CONFUSION; CYANOSIS; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DROWSINESS; DRUG ABSORPTION; DRUG USE; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; FEVER; FLUSHING; GROWTH INHIBITION; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; LACRIMAL DUCT; LETHARGY; MONOTHERAPY; NAUSEA; NECROTIZING ENTEROCOLITIS; PALLOR; PARALYTIC ILEUS; PSYCHOSIS; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; STOMACH DISTENSION; SWEATING; SYNCOPE; SYSTEMIC DISEASE; SYSTEMIC TOXICITY; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TOXICITY; TREMOR; VOMITING; VULNERABLE POPULATION; XEROSTOMIA;

EID: 33845802673     PISSN: 14630095     EISSN: None     Source Type: Journal    
DOI: 10.1185/146300905X75334     Document Type: Review

References (58)

1. Garnier LF. Systemic effects of beta-blocker eye drops. Presse Medicale 1988;17:1260-1262.
2. Diamond JP. Systemic adverse effects of topical ophthalmic agents. implications for older patients. Drugs Aging 1997; 11:352-360.
3. Roarty JD. Ophthalmologic drugs in infants and children. In Yaffe SJ, Aranda JV (editors): Neonatal and Pediatric Pharmacology 3rd ed. Philadelphia 2005: Lippincott Williams & Wilkins: 340-348.
4. Hopkins GA, Lyle WM. Potential systemic effects of six common ophthalmic drugs. J Am Optometric Assoc 1977;48:1241-1245.
5. Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eye drops. Graefes Arch Clin Exp Ophthalmol 2002;240:430-435.
6. Salminen L. Review: systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol 1990;6:243-249.
7. Nelson WL, Fraunfelder FT, Sills JM et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986;102:606-611.
8. Coulter RA. Pediatric use of topical ophthalmic drugs. Optometry 2004;75:419-429.
9. Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr 2004;43:99-101.
10. Rengstorff RH, Doughty CB. Mydriatic and cycloplegic drugs: a review of ocular and systemic complications. Am J Physiol Opt 1982;59:162-177.
11. Royal College of Paediatrics and Child Health. Medicines for Children, 2nd ed. London 2003: RCPCH Publications Limited.
12. Fraunfelder FT, Meyer SM. Systemic reactions to ophthalmic drug preparations. Med Toxicol Adv Drug Exp 1987;2:287-293.
13. Laws DE, Morton C, Weindling M, Clark D. Systemic effects of screening for retinopathy of prematurity. Br J Ophthalmol 1996;80:425-428.
14. Rosales T, Isenberg S, Leake R, Everett S. Systemic effects of mydriatics in low weight infants. J Pediatr Ophthalmol Strabismus 1981;18:42-44.
15. Rush R, Rush S, Nicolau J et al. Systemic manifestations in response to mydriasis and physical examination during screening for retinopathy of prematurity. Retina 2004;24:242-245.
16. Lim DL, Batilando M, Rajadurai VS. Transient paralytic ileus following use of cyclopentolatephenylephrine eye drops during screening for retinopathy of prematurity. J Paediatr Child Health 2003;39:318-320.
17. Hermansen MC, Sullivan LS. Feeding intolerance following ophthalmologic examination. Am J Dis Child 1985;139:367-368.
18. Sarici SU, Yurdakok M, Unal S. Acute gastric dilatation complicating the use of mydriatics in a preterm newborn. Pediatr Radiol 2001;31:581-583.
19. Shinomiya K, Kajima M, Tajika H et al. Renal failure caused by eyedrops containing phenylephrine in a case of retinopathy of prematurity. J Med Invest 2003;50:203-206.
20. Greher M, Hartmann T, Winkler M et al. Hypertension and pulmonary edema associated with subconjunctival phenylephrine in a 2-month-old child during cataract extraction. Anesthesiology 1998;88:1394-1396.
21. Baldwin FJ, Morley AP. Intraoperative pulmonary oedema in a child following systemic absorption of phenylephrine eyedrops. BrJ Anaesth 2002;88:440-442.
22. Awan KJ. Adverse systemic reactions of topical cyclopentolate hydrochloride. Ann Ophthalmol 1976;8:695-698.
23. Pappano AJ, Katzung BG. Cholinoceptor-blocking drugs. In: Katzung B (editor). Basic and Clinical Pharmacology 9th ed. United States of America 2004: The McGraw-Hill Companies Inc: 109-121.
24. Anonymous. Cyclopentolate. PharmGKB: The Pharmacogenetics and Pharmacogenomics Knowledge Base; accessed from www.pharmgkb.org/views/ index on 15 December 2005.
25. Anonymous. Cyclogel™ Data Sheet. Information for Health Professionals; accessed from www.medsafe.govt.nz/profs/datasheet on 15 December 2005.
26. Bhatia SS, Vidyashanker C, Sharma RK, Dubey AK. Systemic toxicity with cyclopentolate eye drops. Indian Pediatr 2000;37:329-331.
27. Fitzgerald DA, Hanson RM, West C et al. Seizures associated with 1% cyclopentolate eye drops. J Paediatr Child Health 1990;26:106-107.
28. Demayo AP, Reidenberg MM. Grand mal seizure in a child 30 minutes after Cyclogyl (cyclopentolate hydrochloride) and 10% Neo-Synephrine (phenylephrine hydrochloride) eye drops were instilled. Pediatrics 2004;113:e499-500.
29. Mwanza JCK. Cyclopentolate and grand mal seizure. Bull Soc Belge Ophthalmol 1999;273:17-18.
30. Vuori ML, Kaila T, Iisalo E, Saari KM. Systemic absorption and anticholinergic activity of topically applied tropicamide. J Ocul Pharmacol 1994;10: 431-437.
31. Bolt B, Benz B, Koerner F, Bossi E. A mydriatic eye-drop combination without systemic effects for premature infants: a prospective double-blind study. J Pediatr Ophthalmol Strabismus 1992;29:157-162.
32. Fan DSP, Rao SK, Ng JSK et al. Comparative study on the safety and efficacy of different cycloplegic agents in children with darkly pigmented irides. Clin Exp Ophthalmol 2004;32:462-467.
33. Anonymous. Paremyd Drug Information. Drugs. com; accessed from www.drugs.com/cons/paremyd.html on 15 December 2005.
34. Hoskins HD, Hetherington J, Magee SD et al. Clinical experience with timolol in childhood glaucoma. Arch Ophthalmol 1985;103:1163-65.
35. Zimmerman TJ, Kooner KS, Morgan KS. Safety and efficacy of timolol in paediatric glaucoma. Surv Ophthalmol 1983;28:S262-S264.
36. Boger WP, Walton DS. Timolol in uncontrolled childhood glaucomas. Ophthalmology 1981;88: 253-258.
37. McMahon CD, Hetherington J, Hoskins HD et al. Timolol and pediatric glaucomas. Ophthalmology 1981;88:249-252.
38. Nygaard HA, Hovding G. Adverse reactions from topical use of beta blocking eye drops. A review of literature and a survey of reports to the Norwegian Medicines Control Authority from 1986 to 1995. Tidsskrift for den Norske Laegeforening 1997;117:2019-2021.
39. Burnstine RA, Felton JL, Ginther WH. Cardiorespiratory reaction to timolol maleate in a paediatric patient: a case report. Ann Ophthalmol 1982;14:905-906.
40. Gray CL. Cardiac and central nervous system toxicity with timolol eye drops in an infant: case report and discussion. Paed Perinat Drug Ther 2006;7:15-18.
41. Olson RJ, Bromberg BB, Zimmerman TJ. Apneic spells associated with timolol therapy in a neonate. Am J Ophthalmol 1979;88:120-122.
42. Hoffman BB. Adrenoceptor-activating & other sympathomimetic drugs. In: Katzung B (editor). Basic and Clinical Pharmacology 9th ed. United States of America 2004: The McGraw-Hill Companies Inc: 109-121.
43. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. JAAPOS 2001;5:281-284.
44. Al-Shahwan S, Al-Torbak AA, Turkmani S et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology 2005;112:2143.
45. Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye 2004;18:24-26.
46. Berlin RJ, Lee UT, Samples JR et al. Ophthalmic drops causing coma in an infant. J Pediatr 2002;140:485-486.
47. Allen DB. Do intranasal corticosteroids affect childhood growth? Allergy 2000;55:S15-18.
48. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000;106:S179-190.
49. Allen DB, Bielory L, Derendorf H et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112:S1-S40.
50. Roters S, Aspacher F, Diestelhorst M. The influence of dexamethasone 0.1% eye drops on plasma cortisol and ACTH concentrations after surgery. Ophthalmologica 1996;210:211-214.
51. Ozerdem U, Levi L, Cheng L et al. Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year old mate with posterior uveitis. Am J Ophthalmol 2000;130:240-241.
52. Steelman J, Kappy M. Adrenal suppression and growth retardation from ocular corticosteroids. J Pediatr Ophthalmol Strabismus 2001;38:177-178.
53. Doona M, Walsh JB. Use of chloramphenicol as topical eye medication: time to cry halt? BMJ 1995;310:1217-1218.
54. McGhee CN, Anastas CN. Widespread ocular use of chloramphenicol: is there justifiable concern regarding idiosyncratic aplastic anaemia? Br J Ophthalmol 1996;80:182-184.
55. Laporte JR, Vidal X, Ballarin E, Ibanez L. Possible association between ocular chloramphenicol and aplastic anaemia-the absolute risk is very low. Br J Clin Pharmacol 1998;46:181-184.
56. Wiholm BE, Parsells Kelly J, Kaufman D et al. Relation of aplastic anaernia to use of chloramphenicol eye drops in two international case-control studies. BMJ 1998;316:666.
57. Wheatcroft S, Sharma A, McAllister J. Reduction of mydriatic drop size in premature infants. Br J Ophthalmol 1993;77:364-365.
58. Ohno Y, Iga T, Yamada Y et al. Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). Curr Eye Res 2005;30: 319-328.